Xencor (XNCR) Competitors $7.65 -0.07 (-0.91%) Closing price 04:00 PM EasternExtended Trading$7.64 -0.01 (-0.13%) As of 04:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock XNCR vs. DNLI, IDYA, TARS, IRON, HRMY, MESO, CGON, ADPT, VCEL, and BEAMShould you be buying Xencor stock or one of its competitors? The main competitors of Xencor include Denali Therapeutics (DNLI), IDEAYA Biosciences (IDYA), Tarsus Pharmaceuticals (TARS), Disc Medicine (IRON), Harmony Biosciences (HRMY), Mesoblast (MESO), CG Oncology (CGON), Adaptive Biotechnologies (ADPT), Vericel (VCEL), and Beam Therapeutics (BEAM). These companies are all part of the "pharmaceutical products" industry. Xencor vs. Its Competitors Denali Therapeutics IDEAYA Biosciences Tarsus Pharmaceuticals Disc Medicine Harmony Biosciences Mesoblast CG Oncology Adaptive Biotechnologies Vericel Beam Therapeutics Xencor (NASDAQ:XNCR) and Denali Therapeutics (NASDAQ:DNLI) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, media sentiment, dividends, institutional ownership and earnings. Is XNCR or DNLI more profitable? Denali Therapeutics has a net margin of 0.00% compared to Xencor's net margin of -121.52%. Xencor's return on equity of -25.75% beat Denali Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Xencor-121.52% -25.75% -18.19% Denali Therapeutics N/A -40.79%-36.39% Do insiders and institutionals hold more shares of XNCR or DNLI? 92.9% of Denali Therapeutics shares are owned by institutional investors. 4.8% of Xencor shares are owned by company insiders. Comparatively, 12.5% of Denali Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. Which has more volatility & risk, XNCR or DNLI? Xencor has a beta of 0.89, indicating that its stock price is 11% less volatile than the S&P 500. Comparatively, Denali Therapeutics has a beta of 1.36, indicating that its stock price is 36% more volatile than the S&P 500. Do analysts recommend XNCR or DNLI? Xencor currently has a consensus price target of $26.43, suggesting a potential upside of 245.47%. Denali Therapeutics has a consensus price target of $33.85, suggesting a potential upside of 134.07%. Given Xencor's higher probable upside, equities research analysts clearly believe Xencor is more favorable than Denali Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Xencor 1 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.75Denali Therapeutics 0 Sell rating(s) 1 Hold rating(s) 13 Buy rating(s) 3 Strong Buy rating(s) 3.12 Which has preferable earnings & valuation, XNCR or DNLI? Xencor has higher earnings, but lower revenue than Denali Therapeutics. Denali Therapeutics is trading at a lower price-to-earnings ratio than Xencor, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioXencor$110.49M4.94-$232.62M-$2.40-3.19Denali Therapeutics$330.53M6.40-$422.77M-$2.80-5.16 Does the media prefer XNCR or DNLI? In the previous week, Xencor had 14 more articles in the media than Denali Therapeutics. MarketBeat recorded 26 mentions for Xencor and 12 mentions for Denali Therapeutics. Denali Therapeutics' average media sentiment score of 0.61 beat Xencor's score of 0.58 indicating that Denali Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Xencor 4 Very Positive mention(s) 4 Positive mention(s) 3 Neutral mention(s) 5 Negative mention(s) 0 Very Negative mention(s) Positive Denali Therapeutics 0 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryDenali Therapeutics beats Xencor on 10 of the 17 factors compared between the two stocks. Get Xencor News Delivered to You Automatically Sign up to receive the latest news and ratings for XNCR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding XNCR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart XNCR vs. The Competition Export to ExcelMetricXencorMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$550.61M$2.48B$5.62B$9.84BDividend YieldN/A1.76%4.61%4.07%P/E Ratio-3.1922.0530.2925.74Price / Sales4.94742.42463.41115.83Price / CashN/A184.4138.2159.48Price / Book0.884.838.826.15Net Income-$232.62M$31.61M$3.25B$265.06M7 Day Performance4.51%3.93%4.05%2.80%1 Month Performance-13.56%3.32%4.32%1.68%1 Year Performance-51.37%13.53%36.25%29.59% Xencor Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)XNCRXencor3.598 of 5 stars$7.65-0.9%$26.43+245.5%-51.7%$550.61M$110.49M-3.19280Analyst RevisionDNLIDenali Therapeutics4.1714 of 5 stars$13.91-0.3%$33.85+143.3%-35.7%$2.03B$330.53M-5.21430News CoverageEarnings ReportAnalyst RevisionGap DownIDYAIDEAYA Biosciences4.4441 of 5 stars$22.84-1.1%$48.09+110.6%-36.0%$2.02B$7M-6.0380Analyst RevisionTARSTarsus Pharmaceuticals1.7863 of 5 stars$50.07+4.6%$66.67+33.1%+99.4%$2.02B$182.95M-21.4950Insider TradeAnalyst RevisionIRONDisc Medicine3.2425 of 5 stars$58.59+1.0%$95.73+63.4%+33.2%$2.01BN/A-13.1130Earnings ReportHRMYHarmony Biosciences4.5741 of 5 stars$34.80+1.8%$51.00+46.6%+4.5%$1.97B$714.73M11.23200Analyst RevisionMESOMesoblast2.4409 of 5 stars$14.70-2.2%$18.00+22.4%+140.7%$1.92B$5.90M0.0080Gap UpCGONCG Oncology1.4725 of 5 stars$23.94-3.7%$55.30+131.0%-20.9%$1.89B$1.14M-13.5361Earnings ReportAnalyst RevisionADPTAdaptive Biotechnologies2.8108 of 5 stars$12.15-0.4%$12.38+1.9%+185.1%$1.86B$178.96M-14.82790Gap DownVCELVericel2.4571 of 5 stars$35.43-2.2%$60.33+70.3%-17.5%$1.83B$237.22M295.27300Positive NewsBEAMBeam Therapeutics2.2919 of 5 stars$17.17-2.6%$48.45+182.2%-28.0%$1.78B$63.52M-3.82510 Related Companies and Tools Related Companies Denali Therapeutics Alternatives IDEAYA Biosciences Alternatives Tarsus Pharmaceuticals Alternatives Disc Medicine Alternatives Harmony Biosciences Alternatives Mesoblast Alternatives CG Oncology Alternatives Adaptive Biotechnologies Alternatives Vericel Alternatives Beam Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:XNCR) was last updated on 8/14/2025 by MarketBeat.com Staff From Our PartnersGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredGenerate up to $5,000/month with 10X less money?The secret to retiring without a million-dollar nest egg. I'm talking about generating enough monthly inco...Investors Alley | SponsoredWhen the levee breaksThe U.S. Treasury just confirmed it plans to borrow $1.01 trillion this quarter—nearly double what was project...Porter & Company | SponsoredBut this $20 American company could control the secretThe "Impossible" Chip That Runs on Pure Light Google's quantum computer shocked the world... but China DEMO...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Xencor, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Xencor With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access